These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21212432)

  • 1. U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.
    Casak SJ; Lemery SJ; Shen YL; Rothmann MD; Khandelwal A; Zhao H; Davis G; Jarral V; Keegan P; Pazdur R
    Oncologist; 2011; 16(1):97-104. PubMed ID: 21212432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C; Pitt M; Moxham T; Stein K
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
    Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
    Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
    Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
    Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
    Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
    Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
    Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
    Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
    Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
    Cramer P; Fink AM; Busch R; Eichhorst B; Wendtner CM; Pflug N; Langerbeins P; Bahlo J; Goede V; Schubert F; Döhner H; Stilgenbauer S; Dreger P; Kneba M; Böttcher S; Mayer J; Hallek M; Fischer K
    Leuk Lymphoma; 2013 Aug; 54(8):1821-2. PubMed ID: 23631654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
    Awan FT; Hillmen P; Hellmann A; Robak T; Hughes SG; Trone D; Shannon M; Flinn IW; Byrd JC;
    Br J Haematol; 2014 Nov; 167(4):466-77. PubMed ID: 25130401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
    Ladyzynski P; Molik M; Foltynski P
    Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
    Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
    Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
    Hillmen P; Cohen DR; Cocks K; Pettitt A; Sayala HA; Rawstron AC; Kennedy DB; Fegan C; Milligan DW; Radford J; Mercieca J; Dearden C; Ezekwisili R; Smith AF; Brown J; Booth GA; Varghese AM; Pocock C;
    Br J Haematol; 2011 Mar; 152(5):570-8. PubMed ID: 21231927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
    Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
    Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab].
    Tsukasaki K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():632-5. PubMed ID: 25831837
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
    Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
    Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Adv Ther; 2011 Jul; 28(7):534-54. PubMed ID: 21725721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
    Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
    Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.